Desmopressin for Central Diabetes Insipidus and Bleeding Disorders

Desmopressin is a synthetic hormone analogue that mimics the natural antidiuretic hormone. It is available in injection, nasal spray, tablet, and solution forms and is primarily used for managing central diabetes insipidus and certain bleeding disorders. It helps reduce excessive urine production and controls bleeding by promoting blood clotting factors.

Desmopressin has several approved uses depending on the formulation and patient condition:

• Central Diabetes Insipidus: Used as antidiuretic replacement therapy in both adults and pediatric patients (4 years and older) to manage excessive urination and thirst caused by insufficient natural antidiuretic hormone production.
• Post head trauma or pituitary surgery: Management of temporary increased urine output and thirst.
• Hemophilia A: For patients with factor VIII coagulant activity greater than 5% without factor VIII antibodies, to maintain hemostasis during surgery and to reduce bleeding in spontaneous or traumatic bleeding episodes.
• von Willebrand Disease Type I (mild to moderate): For patients with factor VIII levels greater than 5%, to maintain hemostasis during surgery and manage bleeding episodes.
• Primary Nocturnal Enuresis: Desmopressin tablets are indicated for this condition to reduce nighttime bedwetting in children and adults, but nasal spray formulations are not indicated due to safety concerns.

Limitations: Desmopressin is ineffective for nephrogenic diabetes insipidus and is not indicated for severe von Willebrand’s disease Type I or patients with abnormal factor VIII antigen.

Desmopressin acetate

Desmopressin is a synthetic analogue of vasopressin, the natural antidiuretic hormone produced by the pituitary gland. It acts on the kidneys to promote water reabsorption, reducing urine volume and helping to control excessive urination seen in central diabetes insipidus. Additionally, desmopressin stimulates the release of clotting factor VIII and von Willebrand factor, thereby helping to control bleeding in certain blood clotting disorders.

Desmopressin Acetate Injection

• Central Diabetes Insipidus: 2 mcg to 4 mcg daily, given by subcutaneous or intravenous injection in one or two divided doses. Dose is individualized based on response; do not dilute for diabetes insipidus use.
• Hemophilia A and von Willebrand Disease: 0.3 mcg/kg body weight (max 20 mcg) by intravenous infusion over 15 to 30 minutes. Preoperative dose 30 minutes before procedure. Repeat doses may be given every 8 to 12 hours as needed, but not more frequently than every 48 hours to avoid tachyphylaxis.

Desmopressin Nasal Spray and Nasal Spray Solution

• Adults: 10 mcg once daily into one nostril up to 40 mcg daily, divided into 2–3 doses if needed.
• Children ≥4 years: Start at 10 mcg once daily into one nostril; titrate up to 30 mcg daily (e.g., 20 mcg morning, 10 mcg at night). Not indicated for children under 4 years or doses below 10 mcg.
• Prime the spray pump before first use and after one week of non-use. Discard after 50 sprays.

Desmopressin Tablets

• Initial dosing usually starts at 0.05 mg twice daily, adjusted individually according to response.
• Recommended dose range: 0.1 mg to 0.8 mg daily divided into 2 or 3 doses. For nocturnal enuresis, starting dose is 0.2 mg at bedtime, titrated up to 0.6 mg.
• Patients switching from nasal spray or injection require careful dose titration based on clinical response and serum sodium.

General: Prior to treatment and periodically during therapy, assess serum sodium, urine volume, and osmolality to monitor efficacy and risk of hyponatremia. Fluid intake should be restricted from 1 hour before dosing to at least 8 hours after to reduce water intoxication risk.

• Known hypersensitivity to desmopressin acetate or any component of the product.
• Moderate to severe renal impairment (creatinine clearance below 50 mL/min).
• Hyponatremia or a history of hyponatremia.
• Known or suspected SIADH.
• Polydipsia or excessive fluid intake.
• Concomitant use with loop diuretics or systemic/inhaled glucocorticoids.
• Illnesses causing fluid or electrolyte imbalance (e.g., gastroenteritis, salt-wasting nephropathies, systemic infections).
• For nasal spray/solution: use in patients with impaired consciousness or severe nasal mucosa conditions compromising absorption.
• Nasally administered forms are not indicated for patients needing doses less than 10 mcg or not in multiples of 10 mcg.

Hyponatremia

Desmopressin can cause severe hyponatremia due to water retention, which can lead to seizures, coma, respiratory arrest, and death. It is contraindicated in patients at increased risk of hyponatremia including those with excessive fluid intake, renal impairment (creatinine clearance

Cardiovascular Effects

Monitor blood pressure during administration as desmopressin may cause hypotension or hypertension, especially in patients with underlying heart disease.

Thrombosis Risk

Use with caution in von Willebrand’s disease Type IIB as desmopressin may cause platelet aggregation and thrombosis.

Hypersensitivity

Severe allergic reactions, including fatal anaphylaxis, have been reported with intravenous and intranasal desmopressin. Treatment should be interrupted if hypersensitivity occurs and permanently discontinued if serious reaction develops.

Nasal Mucosa Abnormalities (Nasal Spray)

Chronic use can cause nasal mucosa changes leading to erratic absorption. Avoid nasal spray in patients with severe nasal congestion, blockage, atrophy, recent nasal surgery, or impaired consciousness.

Fluid Retention

May worsen heart failure, uncontrolled hypertension, or conditions sensitive to volume status. Not recommended in patients at risk for increased intracranial pressure or urinary retention.

Common adverse reactions include headache, nausea, abdominal cramps, flushing, facial erythema and swelling, fluid retention, hypertension, hypotension, tachycardia, and hyponatremic seizures. Severe hypersensitivity reactions and thrombotic events have been reported, especially in patients with von Willebrand’s disease Type IIB. Postmarketing reports for nasal spray also include nasal congestion, rhinitis, nosebleed, sore throat, cough, and upper respiratory infections.

Drugs that increase the risk of hyponatremia, such as tricyclic antidepressants, selective serotonin reuptake inhibitors, chlorpromazine, opiate analgesics, NSAIDs, lamotrigine, oxybutynin, and carbamazepine, require careful monitoring of serum sodium during desmopressin therapy. Concomitant use with vasoconstrictors may elevate blood pressure and may necessitate dose reduction of desmopressin.

Pregnancy

Extensive clinical experience and animal studies have not shown an increased risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes with desmopressin. The drug demonstrates poor placental transfer. Use during pregnancy only if clearly needed.

Lactation

Desmopressin is transferred into human breast milk in negligible amounts. No adverse effects on the breastfed infant are expected. The benefits of breastfeeding should be weighed against the mother's clinical need for desmopressin and any potential infant risks.

Signs of overdose may include confusion, drowsiness, persistent headache, difficulty urinating, and rapid weight gain due to fluid retention. Management includes dose reduction, decreasing administration frequency, or discontinuation. There is no specific antidote for desmopressin overdose.

Storage conditions vary by formulation. Nasal spray and nasal spray solution should be refrigerated at 2° to 8°C (36° to 46°F) and can be kept up to 3 weeks at room temperature (22°C/72°F) when traveling. Store bottle upright. Injection, solution, and tablets storage instructions are not specified in current evidence.